Format

Send to

Choose Destination
Lancet Respir Med. 2017 Jun;5(6):472-473. doi: 10.1016/S2213-2600(17)30180-7. Epub 2017 May 26.

Mesenchymal stem cell treatment for IPF-time for phase 2 trials?

Author information

1
Department of Respiratory Medicine and Laboratory of Molecular and Cellular Pulmonology, Faculty of Medicine, University of Crete, Crete, Greece. Electronic address: kantoniou@med.uoc.gr.
2
Department of Respiratory Medicine and Laboratory of Molecular and Cellular Pulmonology, Faculty of Medicine, University of Crete, Crete, Greece.
PMID:
28664848
DOI:
10.1016/S2213-2600(17)30180-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center